12 completed, 1 active not recruiting, 1 terminated. 14 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 14 | Completed 12, Active not recruiting 1, Terminated 1 |
| Phase 2 | 1 | Active not recruiting 1 |
Follow Rabies: new trials by email Literature Review of Rabies trials Research Report on Rabies
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Trial of Rabies Vaccine（Human Diploid Cell）for Human Use,Freeze-dried Freeze-dried Human Rabies Vaccine（Human Diploid Cell）, Essen, Freeze-dried Human Rabies Vaccine（Human Diploid Cell），Zagreb - Rabies | Phase 1 | Completed | Ningbo Rongan Biological Pharmaceutical Co., Ltd. | 60 | 2025-05-23 | 2026-11-12 |
| SYN023 With Rabies Vaccine in Healthy Pediatric Subjects SYN023, Rabies Vaccine, HRIG - Rabies Post-exposure Prophylaxis | Phase 1 | Completed | Synermore Biologics (Suzhou) Co., Ltd. | 108 | 2024-11-30 | 2026-01-15 |
| A Trial to Evaluate the Safety and Immunogenicity of an Investigational Vaccine for the Prevention of Yellow Fever, and of an Investigational Vaccine for the Prevention of Rabies, in Healthy Adults AVX70120 low dose level, AVX70120 middle dose level, AVX70120 high dose level - Yellow Fever, Rabies | Phase 1 | Completed | AstriVax Therapeutics | 112 | 2024-06-16 | 2026-04-22 |
| A Clinical Trial of Rabies Vaccine（Human Diploid Cell）for Human Use,Freeze-dried in a Population Aged 10-60 Years Rabies Vaccine（Human Diploid Cell）for Human Use,Freeze-dried - Rabies | Phase 1 | Completed | Ab&B Bio-tech Co., Ltd.JS | 80 | 2023-11-27 | 2026-01-02 |
| A Phase Ib/II Study of the Safety and Immunogenicity of the Candidate Rabies Vaccine ChAdOx2 RabG ChAdOx2 RabG, Inactivated Rabies Vaccine - Rabies | Phase 1 / Phase 2 | Active not recruiting | University of Oxford | 174 | 2022-02-17 | 2025-11-18 |
| Safety and Immunogenicity of the Candidate Rabies Vaccine ChAdOx2 RabG ChAdOx2 RabG, Inactivated Rabies Vaccine - Rabies | Phase 1 | Terminated | University of Oxford | 18 | 2020-01-02 | 2024-11-08 |
| Dosage-Escalation Study of the Safety and Immunogenicity of a Novel Rabies Vaccine ChAd155-RG vs. the Comparator RABAVERT Vaccine in Healthy Adult Subjects ChAd155-RG, Placebo, Rabies Vaccine - Rabies, Rabies Immunisation | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 50 | 2019-09-19 | 2024-06-03 |
| A Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Experimental Rabies Vaccine in Healthy Adults Low dose formulation of RG SAM (CNE) vaccine (GSK3903133A), Medium dose formulation of RG SAM (CNE) vaccine (GSK3903133A), Lower dose formulation of RG SAM (CNE) vaccine (GSK3903133A) - Virus Diseases | Phase 1 | Completed | GlaxoSmithKline | 160 | 2019-08-13 | 2024-03-01 |
| A Study to Assess the Safety, Reactogenicity and Immune Response of CureVac's Candidate Rabies mRNA Vaccine in Healthy Adults Rabipur®, Rabies mRNA vaccine CV7202 - Rabies | Phase 1 | Completed | CureVac | 53 | 2018-10-12 | 2024-12-19 |
| Safety and Efficacy of a PIKA Rabies Vaccine Containing the PIKA Adjuvant RABIPUR®, PIKA rabies vaccine, PIKA rabies vaccine with an accelerated regimen - Rabies | Phase 1 | Completed | Yisheng Biopharma (Singapore) Pte. Ltd. | 37 | 2015-02-01 | 2016-01-15 |
| The Safety Research of Freeze-dried Rabies Vaccine（MRC-5 Cell) in Chinese Humans 2.5IU/ml in rabies vaccine （MRC-5 Cell) humans aged 10-20 years old, 2.5IU/ml rabies vaccine （MRC-5 Cell) in humans aged 21-60 years old, 2.5IU/ml rabies vaccine （MRC-5 Cell) in humans(from 10-20 years old) - Rabies, Healthy | Phase 1 | Completed | Beijing Center for Disease Control and Prevention | 40 | 2014-11-01 | 2016-01-20 |
| Safety and Tolerability of CV8102 Alone and in Combination With a Rabies Virus Vaccine in Healthy Adults CV8102, Rabipur, CV8102 + Rabipur - Rabies | Phase 1 | Completed | CureVac | 72 | 2014-09-01 | 2018-06-06 |
| An Open-label, Single-Arm Study to Evaluate the Safety and Rabies Virus Antibody Titers of Intramuscularly Administered Rabies Immune Globulin (Human) RIG-C - Rabies | Phase 1 | Completed | Grifols Therapeutics LLC | 12 | 2014-03-01 | 2014-07-24 |
| RNActive® Rabies Vaccine (CV7201) in Healthy Adults CV7201 mRNA - Rabies | Phase 1 | Completed | CureVac | 101 | 2013-10-01 | 2018-10-29 |
Virus Diseases (1) · Yellow Fever (1)
Infections (14) · Mononegavirales Infections (14) · RNA Virus Infections (14) · Rhabdoviridae Infections (14) · Virus Diseases (13) · Arbovirus Infections (1) · Flaviviridae Infections (1) · Flavivirus Infections (1) · Hemorrhagic Fevers, Viral (1) · Mosquito-Borne Diseases (1) · Vector Borne Diseases (1)
Rabies Vaccines (2) · Caprylates (1) · Floors and Floorcoverings (1) · PIKA adjuvant (1) · Vaccines (1)
CureVac (3) · University of Oxford (2) · Ab&B Bio-tech Co., Ltd.JS (1) · AstriVax Therapeutics (1) · Beijing Center for Disease Control and Prevention (1) · GlaxoSmithKline (1) · Grifols Therapeutics LLC (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · Ningbo Rongan Biological Pharmaceutical Co., Ltd. (1) · Synermore Biologics (Suzhou) Co., Ltd. (1) · Yisheng Biopharma (Singapore) Pte. Ltd. (1)
China (3) · Germany (3) · United States (3) · Belgium (2) · Singapore (1) · Tanzania (1) · United Kingdom (1)
Alexander D Douglas (2) · Franz-Josef Falkner von Sonnenburg, MD (1) · Ingo Meyer, MD (1) · Limin Wijaya (1) · Xianfeng Zhang, Master (1)
PMID 28118938, PMID 28754494, PMID 29983597, PMID 33487468, PMID 35907430, PMID 37821317, PMID 39418686, PMID 42066780
2017 (1)